Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Raw Materials (2022 - 2025)

Historic Raw Materials for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Q3 2025 value amounting to $7.2 million.

  • Rhythm Pharmaceuticals' Raw Materials rose 4300.8% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 4300.8%. This contributed to the annual value of $6.8 million for FY2024, which is 4650.81% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Raw Materials stood at $7.2 million, which was up 4300.8% from $4.5 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Raw Materials' 5-year high stood at $7.2 million during Q3 2025, with a 5-year trough of $2.3 million in Q2 2023.
  • Over the past 4 years, Rhythm Pharmaceuticals' median Raw Materials value was $4.6 million (recorded in 2023), while the average stood at $4.4 million.
  • Over the last 5 years, Rhythm Pharmaceuticals' Raw Materials had its largest YoY gain of 8219.78% in 2024, and its largest YoY loss of 3130.32% in 2024.
  • Rhythm Pharmaceuticals' Raw Materials (Quarter) stood at $2.7 million in 2022, then surged by 69.91% to $4.6 million in 2023, then surged by 46.51% to $6.8 million in 2024, then grew by 5.95% to $7.2 million in 2025.
  • Its Raw Materials stands at $7.2 million for Q3 2025, versus $4.5 million for Q2 2025 and $5.0 million for Q1 2025.